Beam Therapeutics (BEAM) Equity Average: 2019-2025
Historic Equity Average for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $1.0 billion.
- Beam Therapeutics' Equity Average rose 22.33% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 22.33%. This contributed to the annual value of $857.4 million for FY2024, which is negligibly% changed negligibly from last year.
- According to the latest figures from Q3 2025, Beam Therapeutics' Equity Average is $1.0 billion, which was down 7.24% from $1.1 billion recorded in Q2 2025.
- Beam Therapeutics' 5-year Equity Average high stood at $1.1 billion for Q2 2025, and its period low was $334.0 million during Q1 2021.
- In the last 3 years, Beam Therapeutics' Equity Average had a median value of $880.1 million in 2023 and averaged $876.9 million.
- Per our database at Business Quant, Beam Therapeutics' Equity Average surged by 1,007.96% in 2021 and then decreased by 13.84% in 2022.
- Beam Therapeutics' Equity Average (Quarterly) stood at $840.3 million in 2021, then fell by 13.84% to $724.0 million in 2022, then rose by 21.57% to $880.1 million in 2023, then decreased by 13.37% to $762.4 million in 2024, then climbed by 22.33% to $1.0 billion in 2025.
- Its last three reported values are $1.0 billion in Q3 2025, $1.1 billion for Q2 2025, and $928.3 million during Q1 2025.